Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CRISPR-edited pericyte development for myotonic dystrophy type 1
NL-OMON43189Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2018
- Countries
- 1
01
Overview
Open-label trial in myotonic dystrophy type 1 (DM1) (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoints: Generation of genetically corrected pericytes from human skeletal muscle biopsy, Pericyte generation efficiency and 2 more. Started Mar 2018; status: active, not recruiting.
02
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NL-OMON43189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43189.